Trials / Recruiting
RecruitingNCT06081920
A Study of IBI363 in Subjects With Advanced Melanoma
A Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of IBI363 in Subjects With Advanced Melanoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-lable, multicenter Phase II study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced melanoma patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IBI363 | IBI363 monotherapy |
Timeline
- Start date
- 2023-10-19
- Primary completion
- 2025-06-06
- Completion
- 2026-07-31
- First posted
- 2023-10-13
- Last updated
- 2025-05-16
Locations
12 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06081920. Inclusion in this directory is not an endorsement.